Skip to content

Study · Non-randomized trial · n = 8 · 2016

8 results

Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.

Iturrino J, Camilleri M, Acosta A, O'Neill J, Burton D, Edakkanambeth Varayil J, Carlson PJ, Zinsmeister AR, Hurt R

JPEN. Journal of parenteral and enteral nutrition28 Jul 2015Cited by 29 (Europe PMC)

PMID26223941 (opens in a new tab)DOI10.1177/0148607115597644 (opens in a new tab)PepBankPUB-26223941
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, teduglutide numerically reduced overall gut transit versus placebo: 53.4% versus 62.4% (P = .075).

    In plain wordsIn adults with short bowel syndrome, teduglutide numerically reduced gut transit versus placebo, without statistical significance.

    Peptide
    Teduglutide
    Outcome
    DecreaseOverall gut transit at 6 hours
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Overall gut transit (% emptied at 6 hours)
    53.4%
    teduglutide, ± 15 (SD)
    Overall gut transit (% emptied at 6 hours)
    62.4%
    placebo, ± 15.2 (SD)
    P value
    0.075
    teduglutide vs placebo, gut transit

    Source sentences

    Summary
    The overall gut transit (% emptied at 6 hours) was 53.4% ± 15% for TED vs 62.4% ± 15.2% for PLA (P = .075), with no effect on GE (P = .74).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, teduglutide did not affect gastric emptying versus placebo (P = .74).

    In plain wordsIn adults with short bowel syndrome, teduglutide did not affect gastric emptying versus placebo.

    Peptide
    Teduglutide
    Outcome
    No significant changeGastric emptying
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    P value
    0.74
    teduglutide vs placebo, gastric emptying

    Source sentences

    Summary
    The overall gut transit (% emptied at 6 hours) was 53.4% ± 15% for TED vs 62.4% ± 15.2% for PLA (P = .075), with no effect on GE (P = .74).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, urine mannitol excretion was 16.2 ± 3.6 mg with teduglutide versus 11.3 ± 2.2 mg with placebo (P = .20).

    In plain wordsIn adults with short bowel syndrome, teduglutide numerically increased early urine mannitol excretion versus placebo, without statistical significance.

    Peptide
    Teduglutide
    Outcome
    IncreaseUrine mannitol excretion at 0-2 hours
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Urine mannitol excretion 0-2 hours
    16.2 mg
    teduglutide, ± 3.6
    Urine mannitol excretion 0-2 hours
    11.3 mg
    placebo, ± 2.2
    P value
    0.2
    teduglutide vs placebo, 0-2 h mannitol

    Source sentences

    Summary
    TED increased urine mannitol excretion at 0-2 hours (16.2 ± 3.6 mg TED vs 11.3 ± 2.2 mg PLA, P = .20) and 0-8 hours (32.7 ± 5.9 mg PLA vs 48.8 ± 8.9 mg TED, P = .17).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, urine mannitol excretion was 48.8 ± 8.9 mg with teduglutide versus 32.7 ± 5.9 mg with placebo (P = .17).

    In plain wordsIn adults with short bowel syndrome, teduglutide numerically increased urine mannitol excretion over eight hours versus placebo, without statistical significance.

    Peptide
    Teduglutide
    Outcome
    IncreaseUrine mannitol excretion at 0-8 hours
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Urine mannitol excretion 0-8 hours
    48.8 mg
    teduglutide, ± 8.9
    Urine mannitol excretion 0-8 hours
    32.7 mg
    placebo, ± 5.9
    P value
    0.17
    teduglutide vs placebo, 0-8 h mannitol

    Source sentences

    Summary
    TED increased urine mannitol excretion at 0-2 hours (16.2 ± 3.6 mg TED vs 11.3 ± 2.2 mg PLA, P = .20) and 0-8 hours (32.7 ± 5.9 mg PLA vs 48.8 ± 8.9 mg TED, P = .17).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, urine lactulose excretion did not differ between teduglutide and placebo.

    In plain wordsIn adults with short bowel syndrome, urine lactulose excretion did not differ between teduglutide and placebo.

    Peptide
    Teduglutide
    Outcome
    No significant changeUrine lactulose excretion
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Intestinal permeability · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    There were no differences in urine lactulose excretion or lactulose/mannitol ratio (0.024 ± 0.005 TED vs 0.021 ± 0.005 PLA).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  6. 06HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, lactulose/mannitol ratios did not differ: 0.024 ± 0.005 with teduglutide versus 0.021 ± 0.005 with placebo.

    In plain wordsIn adults with short bowel syndrome, lactulose/mannitol ratios did not differ between teduglutide and placebo.

    Peptide
    Teduglutide
    Outcome
    No significant changeLactulose/mannitol ratio
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Intestinal permeability · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Lactulose/mannitol ratio
    0.024 ratio
    teduglutide, ± 0.005
    Lactulose/mannitol ratio
    0.021 ratio
    placebo, ± 0.005

    Source sentences

    Summary
    There were no differences in urine lactulose excretion or lactulose/mannitol ratio (0.024 ± 0.005 TED vs 0.021 ± 0.005 PLA).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  7. 07HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, stool weight was numerically lower with teduglutide than placebo: 77 ± 18 versus 106 ± 43 g (P = .42).

    In plain wordsIn adults with short bowel syndrome, teduglutide numerically reduced stool weight versus placebo, without statistical significance.

    Peptide
    Teduglutide
    Outcome
    DecreaseStool weight over 8 hours
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Gastrointestinal
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Stool weight over 8 hours
    77 g
    teduglutide, ± 18 (SEM)
    Stool weight over 8 hours
    106 g
    placebo, ± 43 (SEM)
    P value
    0.42
    teduglutide vs placebo, stool weight

    Source sentences

    Summary
    Over 8 hours, TED (vs PLA) numerically reduced stool weight (mean ± SEM, 77 ± 18 g TED vs 106 ± 43 g PLA, P = .42) and increased urine volume (408.9 ± 52.2 mL TED vs 365.7 ± 57.3 mL PLA, P = .34).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.
  8. 08HumanNon-randomized trialEfficacy outcome

    In adults with short bowel syndrome, urine volume was numerically higher with teduglutide than placebo: 408.9 ± 52.2 versus 365.7 ± 57.3 mL (P = .34).

    In plain wordsIn adults with short bowel syndrome, teduglutide numerically increased urine volume versus placebo, without statistical significance.

    Peptide
    Teduglutide
    Outcome
    IncreaseUrine volume over 8 hours
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    0.05 mg/kg daily · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Urine volume over 8 hours
    408.9 mL
    teduglutide, ± 52.2 (SEM)
    Urine volume over 8 hours
    365.7 mL
    placebo, ± 57.3 (SEM)
    P value
    0.34
    teduglutide vs placebo, urine volume

    Source sentences

    Summary
    Over 8 hours, TED (vs PLA) numerically reduced stool weight (mean ± SEM, 77 ± 18 g TED vs 106 ± 43 g PLA, P = .42) and increased urine volume (408.9 ± 52.2 mL TED vs 365.7 ± 57.3 mL PLA, P = .34).
    1 context sentence
    Summary · context
    In 8 adults with SBS on HPN, we compared daily subcutaneous TED (0.05 mg/kg) and PLA (crossover design, each treatment 7 days with a 14-day washout) on gut transit, intestinal absorption, and permeability after oral mannitol (200 mg) and lactulose (1 g), as well as stool weight and urine volume over 8 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02099084

Short Bowel Syndrome and Teduglutide Versus Placebo

Mayo Clinicn = 8Jan 2014 to Mar 2015

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 22 Feb 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.